| Cat. No. |
Product Name |
Information |
| PC-43411 |
CDK9-IN-1
CDK9 inhibitor
|
CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays. |
| PC-43342 |
CDK9-IN-2
CDK9 inhibitor
|
CDK9-IN-2 (CDK9 inhibitor II) is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1. |
| PC-43145 |
CCT251545
Wnt inhibitor, CDK8/19 inhibitor
|
CCT251545 is a potent, orally bioavailable inhibitor of Wnt signaling with IC50 of 5 nM, also is a potent and selective chemical probe for CDK8 and CDK19 with >100-fold selectivity over 291 other kinases. |
| PC-43121 |
ON123300
Multi-kinases inhibitor
|
Narazaciclib (ON123300) is a potent, multi-targeted kinase inhibitor with IC50 of 5, 3.9, 26, 26, 9.2 and 11 nM for ARK5, CDK4, PDGFRβ, FGFR1, RET and FYN, respectively. |
| PC-63235 |
CDK inhibitor E9
CDK9 inhibitor
|
CDK inhibitor E9 is a novel CDK inhibitor that can overcomes ABC-mediated resistance of THZ1, functions as a potent, non-covalent inhibitor of CDK9 and a covalent inhibitor of CDK12. |
| PC-63209 |
Alsteropaullone
CDK/GSK3β inhibitor
|
Alsteropaullone (9-Nitropaullone, NSC 705701) is a derivative of kenpaullone, ATP-competitive inhibitor of CDKs and GSK3β, inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E and Cdk5/p25 with IC50 of 35, 15, 200 and 40 nM. |
| PC-43098 |
Ro-3306
CDK1 inhibitor
|
Ro-3306 is a potent, selective, ATP-competitive CDK1 inhibitor with Ki of 35 nM against CDK1/cyclin B1, 10-fold selectivity relative to CDK2/cyclin E and >50-fold relative to CDK4/cyclin D. |
| PC-43037 |
CDKI-73
CDK9 inhibitor
|
Asnuciclib (CDKI-73) is a potent CDK9 inhibitor with Ki of 4 nM, shows cytotoxicity against a broad CLL samples with mean LD50 of 80 nM. |
| PC-42965 |
Kenpaullone
CDK nhibitor
|
Kenpaullone (9-Bromopaullone,NSC-664704) is a potent inhibitor of CDK1/cyclin B with IC50 of 0.4 uM, also inhibited CDK2/cyclin A (IC50=0.68 uM), CDK2/cyclin E (IC50-7.5 uM) and CDK5/p25 (IC50=0.85 uM). |
| PC-42956 |
LY2857785
CDK9 inhibitor
|
LY2857785 is a potenrt, reversible and ATP-competitive CDK9 inhibitor with IC50 of 11 nM, also inhibits CDK8 (IC50=16 nM) and weakly inhibits CDK7 (IC50=246 nM). |
| PC-42944 |
THZ2
CDK7 inhibitor
|
THZ2, an analogue of THZ1 with improved pharmacokinetic features, is a potent, selective CDK7 inhibitor with IC50 of 13.9 nM, displays a 5-fold improved half-life in vivo compared with THZ1. |
| PC-63139 |
TAK-931
Cdc7 inhibitor
|
TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM. |
